Integra LifeSciences (NASDAQ:IART) Reaches New 52-Week High – What’s Next?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) hit a new 52-week high during trading on Monday . The company traded as high as $18.92 and last traded at $18.7530, with a volume of 147081 shares. The stock had previously closed at $18.76.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Wall Street Zen raised shares of Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. Truist Financial cut their price target on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a report on Wednesday, April 15th. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Wells Fargo & Company raised their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Finally, Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Thursday, June 18th. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Integra LifeSciences has an average rating of “Reduce” and a consensus price target of $16.20.

Integra LifeSciences Trading Down 4.2%

The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75. The business’s fifty day moving average is $15.14 and its 200-day moving average is $12.58. The stock has a market capitalization of $1.40 billion, a PE ratio of -2.78, a P/E/G ratio of 1.30 and a beta of 1.24.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The company had revenue of $391.92 million for the quarter, compared to the consensus estimate of $381.81 million. During the same quarter last year, the firm posted $0.41 earnings per share. Integra LifeSciences’s revenue was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Institutional investors have recently added to or reduced their stakes in the company. Glenmede Trust Co. NA increased its stake in Integra LifeSciences by 27.4% during the first quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock worth $9,276,000 after acquiring an additional 211,774 shares during the last quarter. Access Investment Management LLC grew its holdings in shares of Integra LifeSciences by 72.0% during the 1st quarter. Access Investment Management LLC now owns 640,535 shares of the life sciences company’s stock worth $6,034,000 after purchasing an additional 268,085 shares during the period. Bank of America Corp DE increased its position in Integra LifeSciences by 71.4% during the 1st quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after purchasing an additional 589,408 shares in the last quarter. Amundi raised its holdings in Integra LifeSciences by 80.8% in the first quarter. Amundi now owns 19,430 shares of the life sciences company’s stock valued at $183,000 after buying an additional 8,681 shares during the period. Finally, Maverick Capital Ltd. purchased a new position in Integra LifeSciences in the first quarter valued at approximately $679,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.